Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment

In Vivo

Volumn 16, Issue 6, 2002, Pages 459-469

  Roussidis, Andreas E ^a   Karamanos, Nikos K ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Aberrant kinase activity; Cancer; Molecular therapy; Receptor tyrosine kinases; Signal inhibition; Signal transduction

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; ALPHA INTERFERON; ANGIOZYME; ANTISENSE OLIGONUCLEOTIDE; ARSENIC TRIOXIDE; BISPECIFIC ANTIBODY 2B 1; CEP 701; CETUXIMAB; COMPOUND 673928; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ERLOTINIB; GEFITINIB; IMATINIB; INX 4437; MDX 447; MONOCLONAL ANTIBODY; PERTUZUMAB; PREDNISONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE; RECOMBINANT ANTIBODY; SCH 6636; SEMAXANIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL NUCLEUS; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BINDING; DRUG DESIGN; DRUG EFFECT; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOSTIMULATION; INTRACELLULAR MEMBRANE; MUTANT; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; ENZYMOLOGY; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0036862019     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Van Der Geer P, Hunter T and Lindberg RA: Receptor protein-tyrosine kinases and their signal transduction pathway. Annu Rev Cell Biol 10: 251-337, 1994.
2. Hanks SK and Hunter T: Protein kinases 6. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. FASEB J 9(8): 576-596, 1995.
3. Krauss G: Biochemistry of Signal Transduction and Regulation. Wiley-VCH Weinheim, Germany, 2001.
4. Tzanakakis GN, Karamanos NK and Hjerpe A: Effects on glycosaminoglycan synthesis in cultured malignant mesothelioma cells of transforming, epidermal and fibroblast growth factors and their combinations with platelet-derived growth factor. Exp Cell Res 220: 130-137, 1995.
5. Vogel W, Gish GD, Alves F and Pawson T: The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1(1): 13-23, 1997.
6. Shrivastava A, Radziejewski C, Campbell E, Kovac L, McGlynn M, Ryan TE, Davis S, Godfarb MP, Glass DJ, Lemke G and Yancopoulos GD: An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell 1(1): 25-34, 1997.
7. Syrokou A, Tzanakakis GN, Hjerpe A and Karamanos NK: Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves growth factor receptors with tyrosine kinase activity. Biochimie 81: 733-744, 1999.
8. Moscatello DK and Iozzo V: Interaction of proteoglycans with receptor tyrosine kinases. Methods Mol Biol 171: 427-434, 2001.
9. Pasquale EB and Singer SJ: Identification of a developmentally regulated protein-tyrosine kinase by using anti-phosphotyrosine antibodies to screen a cDNA expression library. Proc Natl Acad Sci USA 86(14): 5449-5453, 1989.
10. Ruta M, Burgess W, Givol D, Epstein J, Neiger N, Kaplow J, Crumley G, Dionne C, Jaye M and Schlessinger J: Receptor for acidic fibroblast growth factor is related to the tyrosine kinase encoded by the fms-like gene (FLG). Proc Natl Acad Sci USA 86(22): 8722-8726, 1989.
11. Hubbard SR: Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol 71(3-4): 343-358, 1999.
12. Hanks SK, Quinn AM and Hunter T: The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 241(4861): 42-52, 1988.
13. Schlessinger J: Signal transduction by allosteric receptor oligomerization. Trends Biochem Sci 13(11): 443-447, 1988.
14. Yarden Y and Ullrich A: Growth factor receptor tyrosine kinases. Annu Rev Biochem 57: 443-478, 1998.
15. Chou CK, Dull TJ, Russell DS, Gherzi R, Lebwohl D, Ullrich A and Rosen OM: Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem 262(4): 1842-1847, 1987.
16. McClain DA, Maegawa H, Lee J, Dull TJ, Ulrich A and Olefsky JM: A mutant insulin receptor with defective tyrosine kinase displays no biologic activity and does not undergo endocytosis. J Biol Chem 262(30): 14663-14671, 1987.
17. Russell DS, Gherzi R, Johnson EL, Chou CK and Rosen OM: The protein-tyrosine kinase activity of the insulin receptor is necessary for insulin-mediated receptor down-regulation. J Biol Chem 262(24): 11833-11840, 1987.
18. Honegger AM, Dull TJ, Felder S, Van Obberghen E, Bellot F, Szapary D, Schmidt A, Ullrich A and Schlessinger J: Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51 (2): 199-209, 1987.
19. Chen WS, Lazar CS, Lund KA, Welsh JB, Chang CP, Walton GM, Der CJ, Wiley HS, Gill GN and Rosenfeld MG: Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell 59 (1): 33-43, 1989.
20. Williams LT: Signal transduction by the platelet-derived growth factor receptor. Science 243 (4898): 1564-1570, 1989.
21. Cohen GB, Ren R and Baltimore D: Modular binding domains in signal transduction proteins. Cell 80(2): 237-248, 1995.
22. Hunter T: Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 80: 225-236, 1995.
23. Neel BG and Tonks NK: Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol 9: 193-204, 1997.
24. O'Shea JJ, Gadina M and Schreiber RD: Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell 109 Suppl: S121-S131, 2002.
25. Krugmann S and Welch H: PI 3-kinase. Curr Biol 8 (23): R828, 1998.
26. Anderson RA, Boronenkov IV, Doughman SD, Kunz J and Loijens JC: Phosphatidylinositol phosphate kinases, a multifaceted family of signaling enzymes. J Biol Chem 274 (15): 9907-9910, 1999.
27. Schlessinger J and Bar-Sagi D: Activation of Ras and other signaling pathways by receptor tyrosine kinases. Cold Spring Harb Symp Quant Biol 59: 173-179, 1994.
28. Salh B, Marotta A, Matthewson C, Ahluwalia M, Flint J, Owen D and Pelech S: Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 19 (1B): 731-40, 1999.
29. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schelssinger J, Downward J, Mages ELV, Whittle N, Warfield MD and Seeburg PH: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425, 1984.
30. Hsuan JJ: Oncogene regulation by growth factors. Anticancer Res 13 (6B): 2521-2532, 1993.
31. Kolibaba KS and Druker BJ: Protein tyrosine kinases and cancer. Biochim Biophys Acta 1333(3): F217-248, 1997.
32. Hirschfeld S and Helman L: Diverse roles of insulin-like growth factors in pediatric solid tumors. In Vivo 8(1): 81-90, 1994.
33. Resnik JL, Reichart DB, Huey K, Webster NJ and Seely BL: Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58: 1159-1164, 1998.
34. Chan JM, Stampfer MJ, Giovannucci E, Gann PH., Ma J, Wilkinson P, Hennekens CH and Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279 (5350): 563-566, 1998.
35. Gorgoulis V, Aninos D, Priftis C, Evagelopoulou C, Karameris A, Kanavaros P and Spandidos DA: Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors. In Vivo 6 (3): 291-296, 1992.
36. Hong WK and Ullrich A: The role of EGFR in solid tumors and implications for therapy. Oncol Biother 1: 1-29, 2000.
37. Boulougouris P and Elder J: Epidermal growth factor receptor structure, regulation, mitogenic signalling and effects of activation. Anticancer Res 21 (4A): 2769-2775, 2001.
38. Lui VW and Grandis JR: EGFR-mediated cell cycle regulation. Anticancer Res 22 (1A): 1-11, 2002.
39. Hines SJ, Litz JS and Krystal GW: Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors. Breast Cancer Res Treat 58: 1-10, 1999.
40. De Jong JS, Van Diest PJ, Van Der Valk P and Baak JP: Expression of growth factors, growth factor receptors and apoptosis relates proteins in invasive breast cancer: Relation to apoptotic rate. Breast Cancer Res Treat 66: 201-208, 2001.
41. Robertson SC, Tynan JA and Donoghue DJ: RTK mutations and human syndromes when good receptors turn bad. Trends Genet 16 (6): 265-271, 2000.
42. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS and Berger WH: Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 47 (3): 707-712, 1987.
43. Kaleko M, Rutter WJ and Miller AD: Overexpression of the human insulin like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 10(2): 464-473, 1990.
44. Shih IM and Herlyn M: Autocrine and paracrine roles for growth factors in melanoma. In Vivo 8(1): 113-123, 1994.
45. Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (5405): 290-293, 1973.
46. Kurzrock R, Gutterman JU and Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319 (15): 990-998, 1988.
47. Deininger MW, Goldman JM and Melo JV: The molecular biology of chronic myeloid leukemia. Blood 96 (10): 3343-3356, 2000.
48. Ramakrishnan L and Rosenberg B: abl genes. Biochim Biophys Acta 989 (2): 209-224, 1989.
49. De Jong R, Ten Hoeve J, Heisterkamp N and Groffen J: Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem 270 (37): 21468-21471, 1995.
50. Cortez D, Kadlec L and Pendergast AM: Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15 (10): 5531-5541, 1995.
51. Gabriele L, Phung J, Fukumoto J, Segal D, Wang IM, Giannakakou P, Giese NA, Ozato K and Morse HC 3rd: Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med 190 (3): 411-421, 1999.
52. Uemura N and Griffin JD: The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration. J Biol Chem 274 (53): 37525-37532, 1999.
53. Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB and Griffin JD: p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem 271 (41): 25198-21203, 1996.
54. Sattler M, Salgia R, Shrikhande G, Verma S, Uemura N, Law SF, Golemis EA and Griffin JD: Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem 272 (22): 14320-14326, 1997.
55. Sawyers CL, McLaughlin J and Witte ON: Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 181(1): 307-313, 1995.
56. Sawyers CL, Callahan W and Witte ON: Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70(6): 901-910, 1992.
57. Bissonnette RP, Echeverri F, Mahboubi A and Green DR: Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359 (6395): 552-554, 1992.
58. Zwick E, Bange J and Ullrich A: Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8(1): 17-23, 2002.
59. Sawyers CL: Rational therapeutic intervention in cancer: Kinases as drug targets. Curr Opin Genet Dev 12: 111-115, 2002.
60. Gewirtz AM, Sokol DL and Ratajczak MZ: Nucleic acid therapeutics: State of the art and future prospects. Blood 92(3): 712-736, 1998.
61. James HA and Gibson I: The therapeutic potential of ribozymes. Blood 91(2): 371-382, 1998.
62. Dobra K, Andang M, Syrokou A, Karamanos NK and Hjerpe A: Differentiation of mesothelioma cells is influenced by the expression of proteoglycans. Exp Cell Res 258(1): 12-22, 2000.
63. Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G and Aiken RD: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19(8): 2189-2200, 2001.
64. Wraight CJ, White PJ, McKean SC, Fogarty RD, Venables DJ, Liepe IJ, Edmondson SR and Werther GA: Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides. Nat Biotechnol 18(5): 521-526, 2000.
65. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G and Calabretta B: Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 91(10): 4504-4508, 1994.
66. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV and Calabretta B: Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood 88(3): 1005-1012, 1996.
67. De Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T and Calabretta B: Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells. Leukemia 11(6): 811-819, 1997.
68. Smetsers TF, Linders EH, Van De Locht LT, De Witte TM and Mensink EJ: An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism. Br J Haematol 96(2): 377-381, 1997.
69. Fan Z and Mendelsohn J: Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol 10(1): 67-73, 1998.
70. Farah RA, Clinchy B, Herrera L and Vitetta ES: The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryot Gene Expr 8(3-4): 321-356, 1998.
71. Hudson PJ and Souriau C: Recombinant antibodies for cancer diagnosis and therapy. Expert Opin Biol Ther 1(5): 845-855, 2001.
72. Cragg MS, French RR and Glennie MJ: Signaling antibodies in cancer therapy. Curr Opin Immunol 11(5): 541-547, 1999.
73. Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21(2): 309-318, 1999.
74. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA and Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16(8): 2659-2671, 1998.
75. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9): 2639-2648, 1999.
76. Burris HA 3rd: Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). Semin Oncol 27(2 Suppl 3): 19-23, 2000.
77. Overholser JP, Prewett MC, Hooper AT, Waksal HW and Hicklin DJ: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89(1): 74-82, 2000.
78. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P and Hicklin DJ: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59(20): 5209-5218, 1999.
79. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R and Fidler IJ: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60(11): 2926-2935, 2000.
80. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H and Mendelsohn J: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18(4): 904-914, 2000.
81. Van Denderen J, Hermans A, Meeuwsen T, Troelstra C, Zegers N, Boersma W, Grosveld G and Van Ewijk W: Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia. J Exp Med 169(1): 87-98, 1989.
82. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A and Scheinberg DA: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87(9): 3587-3592, 1996.
83. Bosch GJ, Joosten AM, Kessler JH, Melief CJ and Leeksma OC: Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88(9): 3522-3527, 1996.
84. Cervantes F, Pierson BA, McGlave PB, Verfaillie CM and Miller JS: Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 87(6): 2476-2485, 1996.
85. Pawelec G, Max H, Halder T, Bruserud O, Merl A, Da Silva P and Kalbacher H: BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cell found at low frequency in the repertoire of normal donors. Blood 88(6): 2118-2124, 1996.
86. Klohs WD, Fry DW and Kraker AJ: Inhibitors of tyrosine kinase. Curr Opin Oncol 9(6): 562-568, 1997.
87. Levitt ML and Koty PP: Tyrosine kinase inhibitors in preclinical development. Invest New Drugs 17(3): 213-226, 1999.
88. Chang CJ, Ashendel CL, Geahlen RL, McLaughlin JL and Waters DJ: Oncogene signal transduction inhibitors from medicinal plants. In Vivo 10(2): 185-190, 1996.
89. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S and Rowinsky EK: Phase I and pharmacology study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19(13): 3267-3279, 2001.
90. Baselga J and Averbuch SD: ZD1839 ('Iressa') as an anticancer agent. Drugs 60 Suppl 1: 33-40, 2000.
91. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR and Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6(5): 2053-2063, 2000.
92. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, Ullrich A and Fong TA: Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1(1): 31-41, 1999.
93. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G and Cherrington: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60(15): 4152-4160, 2000.
94. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ and Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56(1): 100-104, 1996.
95. Zimmermann J, Buchdunger E, Mett H, Meyer T and Lydon NB: Potent and selective inhibitors of the Abl-kinase:phenylaminopyrimidine (PAP) derivatives. Bioorg Med Chem Lett 7: 187-192, 1997.
96. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG and Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90(12): 4947-4952, 1997.
97. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1): 139-145, 2000.
98. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5): 561-566, 1996.
99. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96(3): 925-932, 2000.
100. Gambacorti-Passerini C, Le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E and Lydon NB: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23(3): 380-394, 1997.
101. Waller CF, Ali M, Heinzinger M and Lange W: Growth inhibition of Ph+ progenitor cells from CML patients using the tyrosine kinase inhibitor CGP57148B. Anticancer Res 20(2A): 809-814, 2000.
102. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M and Druker B: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9): 645-652, 2002.
103. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R and Talpaz M: Activity of a specific inhibitor of the BCL-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14): 1038-1042, 2001.
104. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 20: 5054-5058, 2001.
105. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato Di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S and Nielsen OS: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358: 1421-1423, 2001.
106. Krystal GW, Honsawek S, Litz J and Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Can Res 6: 3319-3326, 2000.
107. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE and Salgia R: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571. Oncogene 19: 3521-3528, 2000.
108. Golub TR, Barker GF, Lovett M and Gilliland DG: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77(2): 307-316, 1994.
109. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger E, Black PM and Stiles CD: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60(18): 5143-5150, 2000.
110. Gambacorti-Passerini C, Barni R, Le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F and D'Incalci M: Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92(20): 1641-1650, 2000.
111. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM and Melo JV: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood 96(3): 1070-1079, 2000.
112. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN and Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531): 876-880, 2001.
113. Weisberg E and Griffin JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95(11): 3498-3505, 2000.
114. Le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R and Gambacorti-Passerini C: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95(5): 1758-1766, 2000.
115. Von Bubnoff N, Schneller F, Pesche C and Duyster J: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 359: 487-491, 2002.
116. Hofmann WK, Jones LC, Lemp NA, De Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG and Koeffler HP: Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99(5): 1860-1862, 2002.
117. Longley BJ, Reguera MJ and Ma Y: Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25(7): 571-576, 2001.
118. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G and Longley BJ: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; Kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99(5): 1741-1744, 2002.
119. O'Dwyer M: Multifaceted approach to the treatment of bcr-abl-positive leukemias. Oncologist 7 Suppl 1: 30-38, 2002.
120. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, and Bhalla KN: CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96(6): 2246-2253, 2000.
121. Liu WM, Stimson LA and Joel SP: The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: Synergistic interactions with anti-leukaemic agents. Br J Cancer 86(9): 1472-1478, 2002.
122. Thiesing JT, Ohno-Jones S, Kolibaba KS and Druker BJ: Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96(9): 3195-3199, 2000.
123. Porosnicu M, Nimmanapalli R, Nguyen D, Worthington E, Perkins C and Bhalla KN: Co-treatment with As203 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells. Leukemia 15(5): 772-778, 2001.
124. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, Kirschmeier P, Bishop WR and Daley GQ: Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97(5): 1404-1412, 2001.